SNP on chromosome 19 may be good biomarker for aggressive Gleason 7 disease

An article just published on line in Clinical Cancer Research supposedly reports the discovery of a single nucleotide polymorphism or SNP that may be useful in predicting which patients with Gleason 7 disease are most likely to have a more aggressive form of cancer. … READ MORE …

Of genes, SNPs, “association,” personalized medicine, and prostate cancer risk

We lost count some time ago of the number of different single nucleotide polymorphism (SNPs) that had been “associated” in some way or other with risk for prostate cancer and/or with risk for more aggressive forms of prostate cancer in specific sets of people (e.g., Swedes, African-Americans, Ghanaians, Caucasians in general, you name it). … READ MORE …

Genomic risk, prostate cancer, endometrial cancer, linkage?

Under the “And this helps me how?” column we can now add the topic of a possible genetic link between endometrial cancer and prostate cancer (maybe). … READ MORE …

Understanding better how genetic variation may affect prostate cancer risk

Previous research using so-called “genome-wide association studies” or GWAS have suggested that there may be as many as 30 different inherited prostate cancer genetic risk variants. What we don’t know much about yet is the relationships between specific genetic risk variants and the clinical outcomes of patients carrying those variants. … READ MORE …

Genetic markers for prostate cancer in Japanese patients

A large study of genetic markers in Japanese prostate cancer patients has clearly shown that some of the markers of prostate cancer in Caucasians do not appear in Japanese patients whereas new markers appear to be common among Japanese. … READ MORE …

Prostate cancer news report: Sunday, January 24, 2010

In this weekend’s prostate cancer news reports, we have addressed recent publications on:

  • A SNP that may be specifically linked to risk for prostate cancer in African Americans
  • The need for extended biopsies in men with larger prostates who are considering focal treatment for prostate cancer
  • A possible association between diabetes, race, obesity, and risk for prostate cancer progression
  • Neoadjuvant hormone therapy, brachytherapy, and all cause mortality in older patients … READ MORE …

More genetic variants associated with prostate cancer

Two new papers published on line in Nature Genetics have added a total of nine more genetic variants to the number of variants associated with an increased risk for prostate cancer. … READ MORE …

Prostate cancer news reports: Tuesday, July 7, 2009

In today’s news reports we address new data on:

  • The possible association between PSA levels and SNPs
  • Patient age at diagnosis and prostate cancer outcomes
  • Revalidation of the Stephenson nomogram for outcomes after salvage radiation therapy
  • Failure to follow best practices for radiation of bony metastases … READ MORE …

The news report: Friday, April 24, 2009

In today’s news report we touch on papers that address:

  • Genome studies and identification of real genomic risk for prostate cancer
  • More on the potential of 5-ARIs in prevention of prostate cancer
  • Whether we really need more studies on selenium as a potential prostate cancer prevention agent
  • The evolving potential of targeted focal therapy … READ MORE …

The news report: Wednesday, April 22

Today’s news reports deal with:

  • A gene modification that may identify risk for prostate cancer
  • Dietary intervention and prostate cancer management
  • “Elastography” as a possible means to assess risk for prostate cancer
  • Pain management in very late stage disease … READ MORE …

Your Wednesday news summary: November 19, 2008

Today’s reports cover such items as:

  • Disparities in cancer mortality between blacks and whites in the USA
  • Body mass, body fat distribution, and risk for prostate cancer
  • Risk for cancer in male carriers of BRCA mutations
  • A five-SNP genetic marker set and prostate cancer risk
  • Final results of the atrasentan trial in non-metastatic, HRPC patients
  • Is a rising plasma PDGF level an indicator for docetaxel failure? … READ MORE …